Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

ABSTRACT: This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the blood SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.

DISEASE(S): Hepatosplenic T-cell Lymphoma,Non-hodgkin's Lymphoma,Multiple,Hodgkin Disease,Mycoses,Hodgkin's Lymphoma,Mycosis Fungoides,Angioimmunoblastic T-cell Lymphoma,Lymphoma, Non-hodgkin,Lymphoma,Neoplasms, Plasma Cell,Multiple Myeloma

PROVIDER: 2126216 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Project description:This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.

| 2128801 | ecrin-mdr-crc

Analysis of extracellular vesicles from large granular lymphocytic leukemia cell lines

Project description:Large granular lymphocyte leukemia (LGLL) is a rare lymphoproliferative malignancy caused by clonal expansion of granular lymphocytes. Two subgroups, (cytotoxic) T-cell LGLL and natural killer (NK) cell LGLL, are defined based on their cellular origin and expression of characteristic surface molecules. In this study, we performed a comparative proteome profiling of isolated extracellular vesicles (EV) from the T-LGLL cell line MOTN-1 and the NK-LGLL line NKL.

2024-10-17 | PXD053228 | Pride

Project description:T-cell large granular lymphocyte leukemia

| PRJNA919192 | ENA

Homo sapiens

Project description:Large Granular Lymphocyte Leukemia Mesenchymal Stem Cells

| PRJNA160169 | ENA

Involvement of hCMV in the ontogeny of CD4+ T-LGL

Project description:Recent studies suggest the potential involvement of common antigenic stimuli on the ontogeny of monoclonal TCRalphabeta+/CD4+/NKa+/CD8-/+dim T-large granular lymphocyte (LGL) lymphocytosis. Since healthy individuals show (oligo)clonal expansions of hCMV-specific TCRVbeta+/CD4+/cytotoxic/memory T-cells, we investigate the potential involvement of hCMV in the origin and/or expansion of monoclonal CD4+ T-LGL. A detailed characterization of those genes that underwent changes in T-LGL cells responding to hCMV was performed by microarray gene expression profile (GEP) analysis.

2008-09-01 | GSE12488 | GEO

Molecular profiling of LGL leukemia reveals role of sphingolipid signaling of cytotoxic lymphocytes

Project description:We used microarrays to expression profile peripheral blood mononuclear cells (PBMCs) from LGL leukemia patients and control subjects to identify survival pathways that render leukemic LGL resistant to activation induced cell death. Keywords: granular lymphocyte leukemia, PBMC

2008-05-01 | GSE10631 | GEO

Homo sapiens

Project description:Expression data from patients with large granular lymphocyte leukemia

| PRJNA171833 | ENA

Expression data from patients with large granular lymphocyte leukemia

Project description:Our results suggest that STAT3 can be activated independent of key oncogenic driver mutations in its SH2 domain in a subset of patients with large granular lymphocyte disorders. We examined the gene expression pattern in T-LGL leukemias compared to controls, and the impact of the presence of STAT3 mutations on the transcriptional regulation of a specific set of genes previously described.

2012-08-03 | GSE39838 | GEO

Large Granular Lymphocyte Leukemia Mesenchymal Stem Cells

Project description:The bone marrow microenvironment in Large Granular Lymphocyte Leukemia (LGLL) patients has been unexplored for it’s role in the development of cytopenias, which lead to complications resulting in the most prominent causes of morbidity and mortality. We used microarrays on primary mesenchymal stem cell (MSC) cultures isolated from bone marrow aspirates from LGLL patients to identify genetic programs that may lead to the observed profibrotic and extrinsically senescent phenotype.

2013-04-20 | GSE37470 | GEO

Homo sapiens

Project description:ECOG 5998, trial of immunosupressives for the treatment of Large Granular Lymphocyte Leukemia

| PRJNA182551 | ENA